Maxiflo 250 Inhaler (Fluticasone Propionate and Formoterol Fumarate Inhaler)
Description:
Maxiflo 250 Inhaler is a combination inhalation therapy containing Fluticasone Propionate (a corticosteroid) and Formoterol Fumarate (a long-acting bronchodilator). It is used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). This dual-action inhaler helps to reduce airway inflammation and relax bronchial muscles, resulting in improved airflow, reduced symptoms, and better overall respiratory function.
Therapeutic Uses:
Long-term management of bronchial asthma in adults and children
Maintenance treatment of COPD, including chronic bronchitis and emphysema
Prevention of respiratory symptoms such as wheezing, chest tightness, and shortness of breath
Mechanism of Action:
Fluticasone Propionate is an inhaled corticosteroid that acts by inhibiting the release of inflammatory mediators, reducing swelling and irritation in the airways.
Formoterol Fumarate is a long-acting beta-2 adrenergic agonist (LABA) that relaxes the smooth muscles of the airways, resulting in sustained bronchodilation and improved breathing.
Dosage Form:
Metered-Dose Inhaler (MDI)
Strength:
Fluticasone Propionate 250 mcg + Formoterol Fumarate 6 mcg per actuation
Prescription Status:
Prescription-only medication
Note:
Maxiflo 250 Inhaler is intended for regular daily use and is not suitable for the relief of acute asthma attacks. A fast-acting bronchodilator should be used for immediate symptom relief. Rinse the mouth after each use to reduce the risk of oral fungal infections. Use under the supervision of a healthcare professional.
Would you like this description formatted for packaging, B2B catalogs, or online listings?
